drugset / Trial / NCT00310076

Thalidomide in Treating Patients Who Have Undergone Surgery and Chemotherapy for Cancer That Has Spread Throughout the Abdomen Due to Colorectal Cancer or Appendix Cancer

NCT00310076 ↗

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Thalidomide may stop the growth of tumor cells by blocking blood flow to the tumor. Giving thalidomide after surgery and chemotherapy may kill any remaining tumor cells. PURPOSE: This phase II trial is studying how well thalidomide works in treating patients who have undergone surgery and received chemotherapy directly into the abdomen by hyperthermic perfusion for cancer that has spread throughout the abdomen due to colorectal cancer or appendix cancer .

Timeline

Start
2002-10
Primary completion
2011-07
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Thalidomide Other / unclassified — Oral

Indications